CD82 Antikörper (C-Term)

Produktnummer ABIN1887018

Produktdetails anti-CD82 Antikörper

Target: CD82

Bindungsspezifität: C-Term

Reaktivität: Human, Maus, Ratte

Wirt: Kaninchen

Klonalität: Polyklonal

Konjugat: Dieser CD82 Antikörper ist unkonjugiert

Applikation: Western Blotting (WB), ELISA, Immunohistochemistry (IHC)

Aufreinigung: Affinity chromatography purified via peptide column

Immunogen: 15 amino acid peptide from near the carboxy terminus of human KAI1.

Anwendungsinformationen

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Format: Liquid

Buffer: PBS containing 0.02 % sodium azide.

Konservierungsmittel: Sodium azide

Vorsichtsmaßnahmen: WARNING: Reagents contain sodium azide. Sodium azide is very toxic if ingested or inhaled. Avoid contact with skin, eyes, or clothing. Wear eye or face protection when handling. If skin or eye contact occurs, wash with copious amounts of water. If ingested or inhaled, contact a physician immediately. Sodium azide yields toxic hydrazoic acid under acidic conditions. Dilute azide-containing compounds in running water before discarding to avoid accumulation of potentially explosive deposits in lead or copper plumbing.

Handhabung: Avoid freezing and thawing repeatly.

Lagerung: 4 °C/-20 °C

Informationen zur Lagerung: Store at 4 °C for short term use.Store at -20 °C for long term preservation.

Details zu CD82

Target: CD82

Andere Bezeichnung: KAI1 (CD82 Produkte)

Synonyme: AA682076 antikoerper, AL023070 antikoerper, C33 antikoerper, IA4 antikoerper, Kai1 antikoerper, Tspan27 antikoerper, 4F9 antikoerper, GR15 antikoerper, KAI1 antikoerper, R2 antikoerper, SAR2 antikoerper, ST6 antikoerper, TSPAN27 antikoerper, CD82 antigen antikoerper, CD82 molecule antikoerper, Cd82 molecule antikoerper, Cd82 antikoerper, CD82 antikoerper

Hintergrund: KAI1 was initially identified from a T-cell activation study as a four-transmembrane protein that plays an accessory role in T-cell activation, and was later determined to act as a cancer metastasis suppressor gene.This protein is ubiquitously expressed at moderate to high levels in most tissues, but its expression is downregulated during tumor progression.The loss of KAI1 and p53 is associated with poor survival for prostate and other cancer patients.Recently, KAI1 was found to interact with DARC, the Duffy antigen for chemokines using a yeast two hybrid screen.It is thought that tumor cells dislodged from the primary tumor and expressing KAI1 interact with DARC proteins expressed on vascular cells, transmitting a senescent signal to the tumor cells, while tumor cells that have lost KAI1 expression can proliferate and potentially give rise to metastases.At least two isoforms of KAI1 are known to exist.
Synonyms: CD82 antigen, tetraspanin-27, Tspan-27, suppressor of tumorgenicity-6

NCBI Accession: NP_002222

Pathways: p53 Signalweg